Yoshimi Yashiro

Introduction: Breakthroughs in stem cell research (SCR) and regenerative medicine (RM) have attracted significant public attention worldwide. Simultaneously, scientific communities and science policies have tried to establish appropriate governance of SCR and RM. In this context, effective communication between scientific communities and the public is regarded as a key factor. However, the diversity of public attitudes and interests has not been sufficiently examined, especially the differences across countries. Methods: We conducted an international comparison of public attitudes toward SCR and RM. We circulated an internet questionnaire among people in six countries: Japan, South Korea, the United States, the UK, Germany, and France. We collected 100 valid responses from each country, and a total of 600 responses were obtained. Results: Our key findings are the diversity of interests in RM, which can be expressed as user pragmatism, governance and handling of RM, risk, and benefit, and scientific interests. The priority of interests varied across the six countries, and the variations may be influenced by the political, social, cultural, and media contexts of SCR and RM in each country. Conclusion: The implications can contribute to a deeper understanding of the diversity of public attitudes, and bring about an appropriate examination of a wide range of ethical and social concerns of SCR and RM in global contexts.

The discovery of somatic cell nuclear transfer proved that somatic cells can carry the same genetic code as the zygote, and that activating parts of this code are sufficient to reprogram the cell to an early developmental state. The discovery of induced pluripotent stem cells (iPSCs) nearly half a century later provided a molecular mechanism for the reprogramming. The initial creation of iPSCs was accomplished by the ectopic expression of four specific genes (OCT4, KLF4, SOX2, and c-Myc; OSKM). iPSCs have since been acquired from a wide range of cell types and a wide range of species, suggesting a universal molecular mechanism. Furthermore, cells have been reprogrammed to iPSCs using a myriad of methods, although OSKM remains the gold standard. The sources for iPSCs are abundant compared with those for other pluripotent stem cells; thus the use of iPSCs to model the development of tissues, organs, and other systems of the body is increasing. iPSCs also, through the reprogramming of patient samples, are being used to model diseases. Moreover, in the 10 years since the first report, human iPSCs are already the basis for new cell therapies and drug discovery that have reached clinical application. In this review, we examine the generation of iPSCs and their application to disease and development.